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There is considerable interest in the relationship between psychological factors and the 
survival of people with cancer. A growing body of literature suggests that depression and 
anxiety, in particular, are associated with worse subsequent survival [1-3]. 
 
A hitherto neglected aspect of this literature is whether depression and anxiety, which 
commonly co-occur, have similar associations with survival when they are considered 
separately. This question arises from an increasing understanding that depression and 
anxiety are not just aspects of ‘emotional distress,’ but have distinct psychological and 
biological mechanisms [4]. We are unaware of any studies published to date that have 
examined this question. We therefore sought to answer it by conducting an analysis of 
prospectively collected data from a large cohort of patients with common cancers (breast, 
colorectal, gynaecological, lung and prostate cancers) who had completed depression and 
anxiety questionnaires as part of their routine cancer care and for whom we had survival 
data. 
 
The aims of our analysis were to examine the independent associations of depression and 
anxiety with subsequent survival in patients with common cancers by determining: (a) the 
association of depression with subsequent survival in patients with each cancer, with and 
without adjustment for anxiety and (b) the association of anxiety with subsequent survival 




Study design and sample 
We analysed data from patients who had attended outpatient clinics of the Edinburgh, 
Glasgow and Dundee National Health Service (NHS) cancer centres in Scotland, UK. Each of 
these cancer centres provides a full range of diagnostic and treatment services in a large 
urban teaching hospital with outreach clinics in the smaller hospitals of surrounding towns. 
Together the three centres serve a geographically defined area of approximately four 
million people and provide specialist care for the vast majority of patients who have been 
diagnosed with cancer in this region. Patients attending these clinics were asked to 
complete a depression and anxiety questionnaire as part of their routine cancer care. Most 
patients (80%) completed this questionnaire (the main reason that patients did not 
complete the questionnaire was that their oncology appointment had begun before they 
could do so). 
 
We included a patient’s data in this analysis if: (a) they had attended an outpatient oncology 
consultation in a central or outreach cancer clinic between May 12, 2008 and Aug 24, 2011; 
(b) they had completed the depression and anxiety questionnaire (the Hospital Anxiety and 
Depression Scale, HADS) that was used routinely in the cancer clinics [5]; (c) the patient had 
no missing items on the HADS; (d) we could obtain their matched demographic and clinical 
data from the Scottish National Cancer Registry; (e) they had given consent for their 
relevant clinical data to be used for research; and (f) they had a primary breast, colorectal, 
gynaecological, lung or prostate cancer. We chose these cancers because they are the most 
common, they often form the basis for multidisciplinary cancer care (therefore the 
associations between depression and anxiety and survival in each group is clinically useful) 
4 
 
and the number of patients within each grouping was sufficient to estimate these 
associations with acceptable accuracy. 
 
Measures 
Depression and anxiety 
The HADS was routinely given to everyone who attended the cancer clinics in order to 
assess how much depression and anxiety they had experienced over the preceding week [5]. 
The HADS has a total of 14 items; seven items make up the HADS depression subscale and 
seven make up the HADS anxiety subscale. The individual items are each scored from zero 
to three, resulting in maximum depression and anxiety subscale scores of 21, with higher 
scores indicating greater severity.  
 
Demographic and cancer data 
We obtained data on patients’ demographic and cancer characteristics from the NHS 
Scotland Cancer Registry. The Registry systematically collects information from hospitals 
throughout Scotland for all recorded cases of cancer. The data included sex, date of cancer 
diagnosis, age at cancer diagnosis, social deprivation score (calculated using the Scottish 
Index of Multiple Deprivation, based on area of residence at the time of cancer diagnosis; 
see Appendix A for details), primary cancer (see Appendix B for details) and initial cancer 
treatment objective (curative or palliative) which we used as a proxy for cancer severity that 







We obtained data on deaths up to April 30, 2012 (that is, 47 months from the first HADS 
completion on May 12, 2008 and eight months from the last HADS completion on Aug 24, 
2011). These data were obtained from the National Records of Scotland (NRS) database and 
included the date and recorded cause of death of each patient. 
 
Data linkage 
To ensure data security and confidentiality the dataset of the patients’ HADS (depression 
and anxiety) scores was sent to the Information Services Division of NHS Scotland for linkage 
using unique patient identification numbers (Community Health Index numbers) and dates 
of birth. All identifying data were then removed in a one-way linkage to produce the 
anonymised dataset that was used for analysis. The study was approved by the South East 
Scotland Research Ethics Committee, the NHS Scotland Caldicott Guardian Forum, and the 
NHS Scotland Privacy Advisory Committee. 
 
Statistical analyses 
For each patient, we calculated the time to their death from the date they completed the 
HADS. We included deaths from any cause in our analysis because most of the deaths were 
recorded as being due to cancer (see results). If a patient had attended the cancer clinic and 
completed the HADS more than once during the study period, we used the data relating to 
the earliest of these clinic attendances. We censored patients who had left Scotland (at their 
date of emigration) and patients who were not known to have died or to have emigrated at 
the latest date on which data were available (April 30, 2012). Patients whose mortality 
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status was unknown were followed to their last known appointment date (within the study 
period) or were excluded from the analysis if this was unavailable.  
 
We separately analysed the data from patients with each primary cancer (see Appendix B 
for details). Some of the cancers studied are sex-specific (prostate, breast and 
gynaecological). For the other, non-sex specific, cancers (colorectal cancer and lung cancer) 
we conducted separate analyses for males and females because inspection of the data 
suggested sex differences in the associations between anxiety and survival. Our main 
analysis consequently comprised seven sets of models with patients grouped as follows: 
prostate cancer, colorectal cancer – males, lung cancer – males, breast cancer, 
gynaecological cancer, colorectal cancer – females, lung cancer – females. For patients who 
had multiple primary cancers, we used the cancer diagnosis that most closely preceded their 
completion of the HADS to assign them to a group, except where two or more diagnoses 
were made on the same day (nine patients who were given two different cancer diagnoses 
on the same day were included in the analyses of both cancers).  
 
We used Cox proportional hazards models to estimate the associations of depression (HADS 
depression score) and anxiety (HADS anxiety score) with subsequent survival. As expected, 
depression and anxiety scores were associated (Pearson correlation = 0.60, see Appendix C). 
In order to determine their independent associations with survival, we therefore fitted 
models that included both as predictor variables (i.e. we calculated the association of 
depression with survival when adjusted for anxiety and vice versa). Because the associations 
appeared non-linear, we used restricted cubic splines with four knots (positioned at 5th, 35th, 
65th and 95th percentiles) to model the associations of depression and anxiety with survival 
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(we also performed an analysis using cubic splines with five knots, but choose to present 
results for four knots as five knots sometimes produced implausibly steep increases and 
decreases in the fitted relationships).  
 
We also extended these mutually adjusted models to incorporate interactions between 
depression and anxiety scores. In these models we first included all products of the linear 
term for depression and cubic spline terms for anxiety and vice-versa, as is recommended 
[6]. If these interaction terms were jointly statistically significant we additionally compared 
the fit of this model with a simpler one that included only the product of the linear terms for 
depression and anxiety.  
 
Having conducted separate analyses for males and females with each of the non-sex specific 
cancers (colorectal cancer and lung cancer), we performed secondary analyses in which we 
fitted models to all patients with lung cancer and (separately) all patients with colorectal 
cancer that included interactions between sex and the cubic spline terms for depression 
scores and anxiety scores.   
 
In all the models, we adjusted for the following covariates: age at cancer diagnosis, time 
between cancer diagnosis and completion of the HADS, social deprivation score, and initial 
treatment objective recorded at the time of cancer diagnosis. Depression, anxiety and all 
adjustment variables were either inherently or treated as fixed over the follow-up time. We 
expected the associations between continuous adjustment variables (time between cancer 
diagnosis and HADS completion, age at cancer diagnosis and deprivation score) and survival 
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to be non-linear and therefore used restricted cubic splines with four knots to allow flexible 
parameterisation of these relationships.  
 
The models also included two-way interactions between the time interval between cancer 
diagnosis and completion of the HADS and the adjustment variables described above. This 
was because age at cancer diagnosis, social deprivation score and initial cancer treatment 
objective were all measured at the time of patients’ cancer diagnoses and it is plausible that 
the magnitude of their confounding associations with survival may change according to the 
time interval between cancer diagnosis and HADS completion. For each two-way interaction 
between this time interval and either age at cancer diagnosis or social deprivation score, all 
products of linear terms were included in the models. 
 
We used multiple imputation to deal with missing data on initial cancer treatment objective 
(2,533 patients) and social deprivation score (two patients). We used the substantive model 
compatible fully conditional specification (SMCFCS) method for each imputation in order to 
properly account for interactions and non-linear associations [7]. Imputation models could 
include extra variables that were found to be predictive of survival and missingness (see 
Appendix D for further details on the handling of missing data). We performed 20 
imputations (separately for each cancer) using the final model. We fitted Cox regression 
models to each imputed dataset and combined the results using Rubin’s rules [8]. We then 
calculated predicted hazard ratios (HR) at all levels of depression and anxiety for each 
cancer. Imputations were carried out in R version 3.4.1 and all analysis models were fitted in 




We included data from 19,966 patients in the analysis (see Table 1 for their characteristics).  
The median time from HADS completion to death or censoring was 1.9 years (IQR: 1.1, 2.8). 
5,884 patients died (from all causes) during the period of follow-up. Most (91.5%) of the 
deaths were recorded as being due to cancer (see Appendix E).  
 
[Table 1 about here] 
 
 
The fitted associations of depression and anxiety with survival in males and females are 
shown in Figures 1 and 2 respectively (see also Appendix F).  
 
[Figures 1 and 2 about here] 
 
The figures (which are interpreted in detail in the next section) show plots for each of our 
seven groups (prostate cancer, colorectal cancer – males, lung cancer – males, breast 
cancer, gynaecological cancer, colorectal cancer – females, lung cancer – females). The plots 
on the left of each figure show predicted HRs for the association between depression and 
survival, without adjustment for anxiety (red lines) and then with adjustment for anxiety 
(blue lines).  The plots on the right of each figure show predicted HRs for the association 
between anxiety and survival, without adjustment for depression (red lines) and then with 
adjustment for depression (blue lines).  HRs refer to the hazard of mortality for patients with 




The bar chart below each plot shows the percentage of patients with each HADS depression 
or HADS anxiety score; around 90% of patients had depression scores of 10 or less and 
around 90% had anxiety scores of 12 or less.  
 
Association of depression with survival   
Greater depression was strongly associated with worse subsequent survival in all the seven 
groups (p<0.0001 in all groups). The HRs were sizeable, for example the HRs comparing 
patients with HADS depression scores of 10 and 0 varied from 4.30 (95% CI 2.63, 7.06) for 
prostate cancer to 1.81 (95% CI 1.48, 2.22) for lung cancer – females. The fitted 
relationships were not linear, typically being steeper at the lower end of the range than at 
the higher end.  
 
Association of depression with survival when adjusted for anxiety 
When we adjusted for anxiety, the association between depression and survival remained 
statistically significant for all seven groups (p<0.0001). The HRs comparing patients with 
HADS depression scores of 10 and 0 varied from 4.57 (95% CI 2.56, 8.16) for prostate cancer 
to 2.07 (95% CI 1.64, 2.61) for lung cancer – females. For the female groups depression was 
more strongly associated with survival after adjustment for anxiety (see figure 2 blue lines 
compared with red lines). 
 
Association of anxiety with survival   
Greater anxiety was also associated with worse subsequent survival in five of the seven 
groups (prostate cancer p=0.001, colorectal cancer – males p=0.0001, lung cancer – males 
p<0.0001, breast cancer p=0.022, gynaecological cancer p=0.040, colorectal cancer – 
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females p=0.152, lung cancer – females p=0.066).  The HRs observed were however smaller 
than those for depression, for example the HRs comparing patients with HADS anxiety 
scores of 10 and 0 varied from 1.89 (95% CI 1.31, 2.72) for prostate cancer to 0.96 (95% CI 
0.67, 1.39) for colorectal cancer – females.  
 
Association of anxiety with survival when adjusted for depression 
When we adjusted for depression, the association of anxiety with survival changed 
markedly. For males, little or no association between anxiety and survival remained. For 
females, the association of anxiety with survival was typically in the opposite direction to 
that observed before we adjusted for depression. That is to say, greater anxiety was now 
associated with better survival (breast cancer p<0.0001, gynaecological cancer p=0.0002, 
colorectal cancer – females p=0.037, lung cancer – females p=0.019). The HRs comparing 
patients with HADS anxiety scores of 10 and 0 varied from 0.87 (95% CI 0.69, 1.10) for lung 
cancer - females to 0.58 (95% CI 0.39, 0.88) for colorectal cancer - females.  
 
The observed difference between the sexes in the association between anxiety and survival 
was clearest when comparing the plots for the sex-specific cancers. The same directional 
differences were also seen in the sex-specific analyses of the lung and colorectal cancer 
groups, however, formal interaction tests from models including both males and females 
were not statistically significant (colorectal p=0.111, lung p=0.095). 
 
Interaction between depression and anxiety in their associations with survival   
When fitting models with both depression and anxiety and an interaction between the two, 
there was some evidence of an interaction for those with breast cancer (p=0.025) but not 
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for the other cancers. Results from this analysis are presented in Appendix G. We suggest 






We found that, as expected, greater depression was strongly associated with worse 
subsequent survival for both male and female patients for all the cancers we studied. After 
adjusting for anxiety, this association remained in males and became stronger in females. 
We also found that greater anxiety was associated with worse survival in most of the groups 
analysed. However, after adjusting for depression the relationship between anxiety and 
survival changed, disappearing in males and changing direction in females such that greater 
anxiety became associated with better subsequent survival. This negative association of 
greater anxiety and worse survival, coupled with the fact that depression and anxiety are 
highly associated, explains why the association between depression and survival became 
stronger in females after adjusting for anxiety. 
 
Other literature 
The finding that greater depression is associated with worse subsequent survival in people 
with cancer has been frequently reported [1-3], but is disputed on methodological grounds 
[11]. Our findings, from this large methodologically robust study, support this association. 
Although less studied, the finding that greater anxiety is associated with worse survival in 
people with cancer has also been reported [3, 12]. Our finding that, after adjustment for 
depression, this association effectively disappears in males (so that anxiety is no longer 
associated with survival) and actually reverses direction in females (so that greater anxiety is 
associated with better survival) is novel. We are not aware of any previous study of the 
associations of depression and anxiety with survival in patients with cancer that has 
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examined these independent associations. There have however been a small number of 
relevant studies in other populations. In people with cardiac disease, a systematic review 
reported an association between greater anxiety and worse survival, but also that this 
association was weakened when severity of depression was adjusted for, suggesting that 
depression was the more important factor [13]. A large study of patients with suspected 
cardiac disease undergoing exercise testing found, as we did in patients with cancer, that 
after adjustment for depression, anxiety was associated with better, rather than worse 
survival [14]. Studies of the general population have also found that anxiety predicts better 
rather than worse life expectancy [15], and that when anxiety complicates depression the 
association between depression and worse survival is reduced [16]. These similar findings in 
non-cancer populations increase our confidence that our novel findings in patients with 
cancer are meaningful.  
 
Interpretation 
Our results suggest that, whatever the mechanism of the association between depression 
and worse survival in people with cancer, it is specific to depression [17]. Potential 
mechanisms for this association have been proposed, but none proven [18]. It is of interest 
that the relationship between depression and survival was not linear, typically being steeper 
at the lower end of the range than at the higher end. The explanation for this observation is 
unclear. However, we note that mild depression has been associated with worse survival in 
patients with heart disease [19], and small changes in that mild depression over time have 
been associated with improved survival [20]. Our findings in patients with cancer and these 
in patients with heart disease suggest that we should not focus solely on the association 
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between severe depression and survival in patients with medical illnesses, but also consider 
mild and moderate depression. 
 
Anxiety appears to have a different relationship with survival than depression, with no 
association in males and an association with better, not worse, survival in females. This is 
most clearly seen in the female-specific cancers (breast and gynaecological). There are a 
number of potential mechanisms for the association of anxiety with better survival, but 
perhaps the most plausible is that anxiety leads to healthier behaviours, more medical care 
seeking and better adherence to medical treatments [21]. It is of interest that this is only 
clearly observed in female specific cancers and may reflect the importance of patient 
adherence to treatment recommendations in these cancers. 
 
Strengths and limitations 
The strengths of our study were: (a) the use of data from a large representative sample of 
patients with common cancers attending UK NHS cancer centres serving a geographically 
defined area; (b) the availability of continuous measures of depression and anxiety using a 
well-validated scale; (c) a cancer diagnosis and severity assessment done by oncologists; (d) 
an almost complete follow-up of the cohort using individually linked national registry data, 
including data on cause of death and (e) robust analysis of these unique data accounting for 
missing data and controlling for possible confounders, including not only age and sex, but 
also social deprivation (determined by the patient’s address) and initial cancer severity 




Despite these strengths, our study also had limitations including: (a) findings that may not 
necessarily generalise to other populations (such as patients in different healthcare settings 
or those who were diagnosed with cancer many years ago and who no longer attend 
clinics); (b) the assessment of depression and anxiety using self-rating scales which unlike a 
diagnostic interview do not provide diagnoses, but rather a continuous measure of 
symptom severity; (c) some missing data on the HADS score and initial cancer treatment 
objective (which we addressed using multiple imputation in the analysis but we cannot rule 
out the possibility that these data were not missing at random); (d) the completion of the 
HADS at varying intervals after initial cancer diagnosis (although we did take account of this 
in our analysis); (e) a lack of information on the time-course of depression and anxiety 
either prior to or subsequent to the HADS completion; (f) follow-up data on patients for a 
mean of approximately two years from the time of HADS completion but not on all patients 
to the time of their death; (g) an inability to fully adjust for all potential confounders - in 
particular we had to rely on initial treatment objective as a measure of cancer severity as it 
was not possible to combine the different staging systems used for different cancer types in 
our analysis;  (h) an inability to control for medical comorbidities, although it is unlikely that 
these were important in determining survival, as almost all the patient deaths were 
attributed to cancer.  
 
Conclusions 
Depression and anxiety have both been associated with the worse subsequent survival of 
people with common cancers. The findings presented here confirm that depression is 
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associated with survival but also indicate that, when depression is adjusted for, anxiety is 
not. In fact anxiety may even predict better survival in females. The implication of these 
findings is that whatever the mechanism of the association of depression with worse 
survival, it is specific to depression. Depression and anxiety should not therefore be lumped 
together as ‘emotional distress’ but should be considered separately in future studies of the 
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Depression and anxiety have both been reported to predict the worse subsequent survival 
of people with cancer. However, depression and anxiety are mutually associated and we 
lack understanding of their independent associations with survival. We therefore aimed to 
investigate these in a large sample of patients with common cancers. 
  
Methods 
We analysed data on 19,966 patients with common cancers (breast, colorectal, 
gynaecological, lung and prostate) who had attended specialist NHS outpatient clinics in 
Scotland, UK. Hospital Anxiety and Depression Scale (HADS) data were linked with 
demographic, cancer and mortality data. We estimated the independent associations of 
depression (HADS depression score) and anxiety (HADS anxiety score) with survival by fitting 
(separately for each cancer) Cox proportional hazards models which incorporated cubic 
splines to allow for non-linear associations. We also adjusted for potential confounders. 
 
Results  
The median time from HADS completion to death or censoring was 1.9 years. Greater 
depression was found to be strongly associated with worse survival from all cancers. When 
adjusted for anxiety, this association remained in males and increased in females. Greater 
anxiety was also associated with worse survival in nearly all cancers. However, when 
adjusted for depression, the association of anxiety with worse survival was lost. In females 




Although often considered together as aspects of ‘emotional distress’, depression and 
anxiety have different independent associations with survival in patients with cancer and 
should therefore be considered separately. 
 
 







These appendices have been provided by the authors to give readers additional information 
about their work. 
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Appendix A: Social deprivation scores 
Social deprivation was calculated using the Scottish Index of Multiple Deprivation (SIMD) 
2009.  
 
This provides a relative measure of deprivation based on indicators from 7 domains – 
income, employment, health, education, access, housing and crime by dividing Scotland into 
6,505 small geographical areas or divisions (datazones) and ranking these from the most 
deprived (ranked 1) to the least deprived (ranked 6,505). 
 
Reference 
Office of the Chief Statistician. Scottish Index of Multiple Deprivation 2009 Technical Report: 




Appendix B: Cancer groupings 
Grouping ICD-10 
codes* Diagnoses 
Breast C500 Malignant neoplasm of nipple and areola 
 C501 Malignant neoplasm of central portion of breast 
 C502 Malignant neoplasm of upper-inner quadrant of breast 
 C503 Malignant neoplasm of lower-inner quadrant of breast 
 C504 Malignant neoplasm of upper-outer quadrant of breast 
 C505 Malignant neoplasm of lower-outer quadrant of breast 
 C506 Malignant neoplasm of axillary tail of breast 
 C508 Malignant neoplasm, overlapping lesion of breast 
 C509 Malignant neoplasm of breast, unspecified 
 
Lung C340 Malignant neoplasm of main bronchus 
 C341 Malignant neoplasm of upper lobe, bronchus or lung 
 C342 Malignant neoplasm of middle lobe, bronchus or lung 
 C343 Malignant neoplasm of lower lobe, bronchus or lung 
 C348 Malignant neoplasm of overlap les of bronchus & lung 
 C349 Malignant neoplasm of bronchus or lung, unspecified 
 C450 Mesothelioma of pleura 
 C451 Mesothelioma of peritoneum 
 C452 Mesothelioma of pericardium 
 C457 Mesothelioma of other sites 




Colorectal C182 Malignant neoplasm of ascending colon 
 C183 Malignant neoplasm of hepatic flexure 
 C184 Malignant neoplasm of transverse colon 
 C185 Malignant neoplasm of splenic flexure 
 C186 Malignant neoplasm of descending colon 
 C187 Malignant neoplasm of sigmoid colon 
 C188 Malignant neoplasm overlapping lesion of colon 
 C189 Malignant neoplasm of colon, unspecified 
 C19X Malignant neoplasm of rectosigmoid junction 
 C20X Malignant neoplasm of rectum 
 
Gynaecological C481 Malignant neoplasm of specified parts of peritoneum 
 C482 Malignant neoplasm of peritoneum, unspecified 
 C510 Malignant neoplasm of labium majus 
 C511 Malignant neoplasm of labium minus 
 C512 Malignant neoplasm of clitoris 
 C518 Malignant neoplasm of overlapping lesion of vulva 
 C519 Malignant neoplasm of vulva, unspecified 
 C52X Malignant neoplasm of vagina 
 C530 Malignant neoplasm of endocervix 
 C531 Malignant neoplasm of exocervix 
 C538 Malignant neoplasm, overlapping lesion of cervix uteri 
 C539 Malignant neoplasm of cervix uteri, unspecified 
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 C540 Malignant neoplasm of isthmus uteri 
 C541 Malignant neoplasm of endometrium 
 C542 Malignant neoplasm of myometrium 
 C543 Malignant neoplasm of fundus uteri 
 C548 Malignant neoplasm overlapping lesion of corpus uteri 
 C549 Malignant neoplasm of corpus uteri, unspecified 
 C55X Malignant neoplasm of uterus, part unspecified 
 C56X Malignant neoplasm of ovary 
 C570 Malignant neoplasm of fallopian tube 
 C571 Malignant neoplasm of broad ligament 
 C572 Malignant neoplasm of round ligament 
 C573 Malignant neoplasm of parametrium 
 C574 Malignant neoplasm of uterine adnexa, unspecified 
 C577 Malignant neoplasm of other specified female genital organs 
 C578 Malignant neoplasm, overlapping lesion female genital organs 
 C579 Malignant neoplasm of female genital organ, unspecified 
 C763 Malignant neoplasm of pelvis 
 
Prostate C61X Malignant neoplasm of prostate 
 





Appendix C: Sunflower plot of HADS-Anxiety versus HADS-Depression scores 
 
 
A blue circle represents one patient.  
A light hexagon with: one vertical line (two radii) represents two patients, three radii 
represents three patients...12 radii represents 12 patients. 





Appendix D: The handling of missing data 
We imputed missing data using the substantive model compatible fully conditional 
specification (SMCFCS) method, an extension of the more common fully conditional 
specification (FCS).  This method imputes missing data across multiple covariates using an 
imputation model that is fully compatible with our substantive (intended) analysis model.  
For our study this may be more appropriate than FCS because we have specified non-linear 
associations and interactions in our regression model, which cannot be completely specified 
in FCS imputation. The imputation models were specified with the substantive model 
variables plus extra variables that, over and above those in the substantive model both (1) 
predict the values of the missing data and (2) predict the probability of these data being 
missing.  We determined this using logistic regression on the complete data where the 
outcome is the variable in question (1) or a 0/1 indicator of its missingness (2). We add to 
the imputation model those variables that were statistically significant at the 5% level for 
both.  We included tumour grade and/or clinical stage marker (as available) for each cancer 
type where there was evidence that these were associated with both survival and 
missingness.  We also did not include any of these extra variables in the substantive models 
for survival since we wanted to use a common set of covariates throughout in order to make 
the cancer-specific results comparable.  
 
References 
Bartlett J. SMCFCS: Multiple Imputation of Covariates by Substantive Model Compatible 





Appendix E: Primary causes of death for patients included in the analysis 
Total number of deaths 5884 
Cancer 5386 (91.5%) 
   Lung 2708 
   Breast  816 
   Gynaecological  753 
   Colorectal  665 
   Prostate  214 
   Other cancer  230 
Circulatory   218 (3.7%) 
   Ischaemic heart disease (including acute myocardial infarction)  111 
   Aortic aneurysm   12 
   Cardiac arrhythmia    7 
   Cerebrovascular disease   59 
   Heart failure    6 
   Other   23 
Respiratory    93 (1.6%) 
   Chronic obstructive airways disease   56 
   Respiratory infection   25 
   Interstitial pulmonary disease    6 
   Other     6 
Gastro-intestinal     41 (0.7%)  
Infection (non-respiratory)   23 (0.4%) 
Injury, poisoning and external causes   21 (0.4%) 
   Fall   10 












   Poisoning (accidental)    4 
   Road traffic accident    1 
   Drowning (undetermined intent)    1  
   Shooting (intentional self-harm)    1 
   Exposure to excessive cold    1 
Neurological   15 (0.3%) 
Renal   12 (0.2%)    
Haematological    12 (0.2%) 
Hepatic, pancreatic or biliary   12 (0.2%) 
Endocrine, nutritional or metabolic     8 (0.1%) 
Mental and behavioural     7 (0.1%) 
   Dementia    6 
   Alcohol dependence    1 
Other    4 (0.1%) 
Unknown   32 (0.5%) 
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Appendix F: Parameter estimates for the models relating HADS-D and HADS-A to mortality 
hazard 
For HADS (either HADS-D or HADS-A), with knots at 𝑘𝑘𝑖𝑖 , 𝑖𝑖 = 1, . . ,4 define the restricted cubic 
spline variables to be created as HADS1, HADS2 and HADS3 as follows. 
HADS1 = HADS 
HADS𝑖𝑖+1
=
(HADS − 𝑘𝑘𝑖𝑖)+3 − (𝑘𝑘4 − 𝑘𝑘3)−1{(HADS − 𝑘𝑘3)+3 (𝑘𝑘4 − 𝑘𝑘𝑖𝑖) − (HADS − 𝑘𝑘4)+3 (𝑘𝑘3 − 𝑘𝑘𝑖𝑖)}
(𝑘𝑘4 − 𝑘𝑘1)2
  
for 𝑖𝑖 = 1, 2 where (𝑢𝑢)+ = 𝑢𝑢, if 𝑢𝑢 > 0 or 0, if 𝑢𝑢 ≤ 0.  
 
The estimated log hazard ratios, p-values and 95% confidence intervals (CI) for each of the 
cancer groupings are as follows: 
Prostate cancer 
Predictor variable  Log hazard ratio p-value 95% CI 
Unadjusted (n=1531 for HADS-D and HADS-A models) 
HADS-D1 0.46 p=0.008 0.12, 0.80 
HADS-D2 -1.82 p=0.122 -4.14, 0.49 
HADS-D3 3.52 p=0.167 -1.48, 8.51 
HADS-A1 0.07 p=0.532 -0.16, 0.30 
HADS-A2 -0.04 p=0.966 -1.76, 1.68 
HADS-A3 0.05 p=0.976 -3.12, 3.21 
Adjusted (n=1531) 
HADS-D1 0.49 p=0.006 0.14, 0.84 
HADS-D2 -1.92 p=0.108 -4.25, 0.42 
HADS-D3 3.66 p=0.154 -1.38, 8.71 
HADS-A1 -0.08 p=0.494 -0.32, 0.16 
HADS-A2 0.43 p=0.633 -1.33, 2.18 





Colorectal cancer – males 
Predictor variable  Log hazard ratio p-value 95% CI 
Unadjusted (n=1573 for HADS-D and HADS-A models) 
HADS-D1 0.09 p=0.348 -0.10, 0.28 
HADS-D2 0.15 p=0.826 -1.21, 1.51 
HADS-D3 -0.40 p=0.752 -2.87, 2.07 
HADS-A1 0.03 p=0.765 -0.15, 0.20 
HADS-A2 0.50 p=0.449 -0.79, 1.78 
HADS-A3 -1.03 p=0.392 -3.38, 1.32 
Adjusted (n=1573) 
HADS-D1 0.08 p=0.408 -0.11, 0.28 
HADS-D2 0.10 p=0.890 -1.28, 1.48 
HADS-D3 -0.26 p=0.838 -2.77, 2.25 
HADS-A1 -0.02 p=0.821 -0.20, 0.16 
HADS-A2 0.47 p=0.484 -0.84, 1.78 
HADS-A3 -0.96 p=0.431 -3.36, 1.43 
Lung cancer – males 
Predictor variable Log hazard ratio p-value 95% CI 
Unadjusted (n=2299 for HADS-D and HADS-A models) 
HADS-D1 0.10 p=0.002 0.04, 0.17 
HADS-D2 -0.11 p=0.498 -0.41, 0.20 
HADS-D3 0.17 p=0.601 -0.47, 0.81 
HADS-A1 0.05 p=0.175 -0.02, 0.11 
HADS-A2 -0.03 p=0.858 -0.32, 0.27 
HADS-A3 0.06 p=0.895 -0.79, 0.90 
Adjusted (n=2299) 
HADS-D1 0.11 p=0.001 0.04, 0.18 
HADS-D2 -0.12 p=0.433 -0.44, 0.19 
HADS-D3 0.20 p=0.540 -0.45, 0.85 
HADS-A1 -0.03 p=0.458 -0.10, 0.04 
HADS-A2 0.09 p=0.552 -0.21, 0.39 





Predictor variable Log hazard ratio p-value 95% CI 
Unadjusted (n=8467 for HADS-D and HADS-A models) 
HADS-D1 1.36 p<0.001 1.15, 1.60 
HADS-D2 0.22 p=0.011 0.07, 0.71 
HADS-D3 24.41 p=0.013 1.95, 306.04 
HADS-A1 1.08 p=0.077 0.99, 1.18 
HADS-A2 0.74 p=0.084 0.53, 1.04 
HADS-A3 2.49 p=0.068 0.94, 6.63 
Adjusted (n=8467) 
HADS-D1 1.41 p<.001 1.19, 1.67 
HADS-D2 0.24 p=0.018 0.07, 0.78 
HADS-D3 19.18 p=0.024 1.49, 247.41 
HADS-A1 1.00 p=0.935 0.92, 1.10 
HADS-A2 0.78 p=0.156 0.56, 1.10 
HADS-A3 2.10 p=0.144 0.78, 5.65 
Gynaecological cancer 
Predictor variable Log hazard ratio p-value 95% CI 
Unadjusted (n=2910 for HADS-D and HADS-A models) 
HADS-D1 0.35 p<.001 0.18, 0.51 
HADS-D2 -1.65 p=0.004 -2.79, -0.51 
HADS-D3 2.85 p=0.007 0.79, 4.92 
HADS-A1 0.06 p=0.189 -0.03, 0.15 
HADS-A2 -0.07 p=0.718 -0.44, 0.30 
HADS-A3 0.04 p=0.946 -1.05, 1.12 
Adjusted (n=2910) 
HADS-D1 0.38 p<.001 0.21, 0.55 
HADS-D2 -1.69 p=0.004 -2.84, -0.54 
HADS-D3 2.94 p=0.006 0.86, 5.02 
HADS-A1 -0.02 p=0.666 -0.11, 0.07 
HADS-A2 0.01 p=0.973 -0.37, 0.38 




Colorectal cancer – females 
Predictor variable Log hazard ratio p-value 95% CI 
Unadjusted (n=1154 for HADS-D and HADS-A models) 
HADS-D1 0.21 p=0.131 -0.06, 0.48 
HADS-D2 -0.60 p=0.530 -2.48, 1.27 
HADS-D3 0.90 p=0.605 -2.50, 4.29 
HADS-A1 -0.16 p=0.073 -0.33, 0.01 
HADS-A2 0.78 p=0.055 -0.02, 1.58 
HADS-A3 -1.66 p=0.062 -3.40, 0.08 
Adjusted (n=1154) 
HADS-D1 0.30 p=0.038 0.02, 0.57 
HADS-D2 -1.02 p=0.290 -2.91, 0.87 
HADS-D3 1.63 p=0.351 -1.79, 5.05 
HADS-A1 -0.23 p=0.010 -0.41, -0.06 
HADS-A2 0.89 p=0.031 0.08, 1.70 
HADS-A3 -1.85 p=0.039 -3.61, -0.09 
Lung cancer – females 
Predictor variable Log hazard ratio p-value 95% CI 
Unadjusted (n=2041 for HADS-D and HADS-A models) 
HADS-D1 0.11 p=0.003 0.04, 0.18 
HADS-D2 -0.25 p=0.142 -0.59, 0.08 
HADS-D3 0.49 p=0.170 -0.21, 1.20 
HADS-A1 0.07 p=0.041 0.00, 0.13 
HADS-A2 -0.17 p=0.114 -0.39, 0.04 
HADS-A3 0.47 p=0.143 -0.16, 1.10 
Adjusted (n=2041) 
HADS-D1 0.12 p=0.002 0.04, 0.19 
HADS-D2 -0.25 p=0.154 -0.59, 0.09 
HADS-D3 0.48 p=0.184 -0.23, 1.19 
HADS-A1 0.02 p=0.529 -0.05, 0.09 
HADS-A2 -0.14 p=0.209 -0.36, 0.08 
HADS-A3 0.39 p=0.231 -0.25, 1.02 
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Appendix G: Plots of the estimated hazard ratios for depression at three levels of anxiety 
(left panel) and estimated hazard ratios for anxiety at three levels of depression (right 
panel) relative to a participant with breast cancer with HADS-D/HADS-A equal to zero.  
 
Predicted hazard ratios for depression severity (at HADS-A=0, 5 and 10) and anxiety severity 
(at HADS-D=0, 5 and 10) for those with breast cancer are shown below. There was no 
evidence that a model with all the products of the linear term for depression and cubic 
spline terms for anxiety and vice-versa fitted better than a simpler model with just the 
product of the linear terms. Therefore, we present the results from this simpler model. The 
figure shows a difference in the shapes of the relationship between anxiety and hazard of 
mortality (with a change in the association with increasing anxiety, from close to zero to 
protective, as depression increases). Differences in the shape of the relationship between 
depression and hazard of mortality across levels of anxiety were less stark, with a slightly 











Plots show predicted hazard ratios (hazard of mortality for patients with each HADS-D or HADS-A score relative to 
patients with a score of zero). Bar Charts show the percentage of patients with each HADS-D and HADS-A score.  Red 
lines show unadjusted hazard ratios (prostate cancer HADS-D p<0.0001, HADS-A p=0.0013; colorectal cancer – males 
HADS-D p<0.0001, HADS-A p=0.0001; lung cancer – males HADS-D p<0.0001, HADS-A p<0.0001). Blue lines show the 
hazard ratios adjusted for the other symptom (depression or anxiety) of interest (prostate cancer HADS-D p<0.0001, 
HADS-A p=0.8401; colorectal cancer – males HADS-D p<0.0001, HADS-A p=0.4586; lung cancer – males HADS-D 
p<0.0001, HADS-A p=0.8798). Note that y-axis scales are different for HADS-D and HADS-A, but consistent across 
cancers. 
  






Plots show predicted hazard ratios (hazard of mortality for patients with each HADS-D or HADS-A score relative to 
patients with a score of zero). Bar Charts show the percentage of patients with each HADS-D and HADS-A score. Red 
lines show unadjusted hazard ratios (breast cancer HADS-D p<0.0001, HADS-A p=0.0220; gynaecological cancer 
HADS-D p<0.0001, HADS-A p=0.0398; colorectal cancer - females HADS-D p=0.0001, HADS-A p=0.1521; lung cancer - 
females HADS-D p<0.0001, HADS-A p=0.0656). Blue lines show the hazard ratios adjusted for the other symptom 
(depression or anxiety) of interest (breast cancer HADS-D p<0.0001, HADS-A p<0.0001; gynaecological cancer HADS-
D p<0.0001, HADS-A p=0.0002; colorectal cancer - females HADS-D p<0.0001, HADS-A p=0.0371; lung cancer - 
females HADS-D p<0.0001, HADS-A p=0.0186). Note that y-axis scales are different for HADS-D and HADS-A, but 
consistent across cancers. 


















Total 1531a 1573 2299 8467 a 2910 a 1154 2041 
Sex 
  Female 








 0 (0%) 
2910 (100%) 





Age at cancer diagnosis [median 
years, IQR] 
66 [62, 72]  65 [59, 72] 68 [61, 74] 57 [49, 66] 60 [50, 69] 65 [57, 72] 67 [60, 74] 
SIMD score quintile b 
   1 
   2 
   3 
   4 
   5 
   Missing 
262 (17%) 
 251 (16%) 
 254 (17%) 
 334 (22%) 
 430 (28%) 














 1547 (18%) 
 1539 (18%) 
 1630 (19%) 
 2308 (27%) 
 1 (0%) 
617 (21%) 
 617 (21%) 
 555 (19%) 
 546 (19%) 
 575 (20%) 













Initial cancer treatment objective 
   Curative 
   Palliative 
   Missing 
635 (41%) 
 634 (41%) 








 466 (6%) 
 1468 (17%) 
2010 (69%) 
 521 (18%) 







Time interval between cancer 
diagnosis & HADSc completion 
[median years, IQR] 
2.0 [0.8, 4.4]  1.0 [0.3, 2.5] 0.3 [0.1, 0.8] 2.0 [0.4, 5.2] 1.0 [0.4, 2.9] 1.0 [0.3, 2.6] 0.3 [0.1, 0.9] 
HADS 
   HADS-D (median, IQR) 
   HADS-A (median, IQR) 
3 [1, 6] 
4 [1, 7] 
3 [1, 6] 
4 [1, 7] 
6 [3, 9] 
5 [3, 9] 
3 [1, 6] 
5 [3, 9] 
4 [1, 7] 
5 [2, 8] 
3 [1, 7] 
5 [2, 8] 
6 [3, 9] 
7 [4, 10] 
Time from HADS completion to death 
or censoring [median years, IQR] 
2.2 [1.7, 3.1]  1.8 [1.2, 2.8] 0.8 [0.3, 1.4] 2.3 [1.6, 3.0] 1.9 [1.2, 2.8] 1.8 [1.2, 2.7] 0.9 [0.4, 1.6] 
Died during study period 288 (19%) 518 (33%) 1603 (70%) 1000 (12%) 824 (28%) 328 (28%) 1328 (65%) 
 
Data are n (%) unless stated otherwise.  a9 patients are included in this table twice because they were diagnosed with more than one primary cancer on the same day: 1 had breast & 
gynaecological cancers, 3 had colorectal & gynaecological cancers, 2 had breast & lung cancers, 1 had breast & colorectal cancers, 1 had colorectal & lung cancers (male), 1 had colorectal & 
prostate cancers. bScottish Index of Multiple Deprivation quintile score: 1=most deprived, 5=least deprived. cHospital Anxiety and Depression Scale: HADS-D=depression severity, HADS-
A=anxiety severity 
